On Tuesday, October 2, 2025, Tilray Brands announced it would expand production of its premium Tilray Craft cannabis at its German facility, adding five new cannabis flower products tailored for physicians and pharmacies.
The move is part of Tilray’s strategy to strengthen its international medical cannabis business, where it already holds the #1 reimbursed medical cannabis market share in Germany. The new products will be available to physicians and pharmacies, potentially increasing Tilray’s revenue in the German market.
Germany remains a key market for Tilray, with EMEA revenues exceeding $323 million compared to U.S. revenues below $274 million. Adding five new flower products is expected to enhance Tilray’s market share and support growth in its most profitable international segment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.